Stock Events

Stock Events

Benitec Biopharma 

$12.18
0
+$0+0% Today

Statistics

Day High
12.18
Day Low
12.18
52W High
-
52W Low
-
Volume
15
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jun 18
$0
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

18MayExpected
Q3 2025
Q4 2025
Next
-0.45
-0.37
-0.3
-0.22
Expected EPS
-0.275
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BNTC.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Benitec's gene-silencing technologies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a direct competitor in the RNA-based therapeutic space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, competing in the same gene-silencing niche.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics is involved in genetic modulation, including RNA-targeted therapies, positioning it as a competitor in genetic disease treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disease treatments, overlapping with Benitec's target market.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genomic medicine, including gene therapy, gene editing, and gene regulation, competing in the broader genetic treatment market.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene editing, a different but competing approach to treating genetic diseases compared to Benitec's gene-silencing.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space, specifically CRISPR, offering alternative genetic disease treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in CRISPR-based gene editing, providing competitive technologies for genetic disease treatment.

About

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Show more...
CEO
ISIN
US08205P2092

Listings

XNAS
US
BNTC
BOATS
BOATS
BNTC.BOATS

0 Comments

Share your thoughts

FAQ

What is Benitec Biopharma stock price today?▼
The current price of BNTC.BOATS is $12.18 USD — it has increased by +0% in the past 24 hours. Watch Benitec Biopharma stock price performance more closely on the chart.
What is Benitec Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Benitec Biopharma stocks are traded under the ticker BNTC.BOATS.
When is the next Benitec Biopharma earnings date?▼
Benitec Biopharma is going to release the next earnings report on May 18, 2026.
What were Benitec Biopharma earnings last quarter?▼
BNTC.BOATS earnings for the last quarter are -0.26 USD per share, whereas the estimation was -0.22 USD resulting in a -16.42% surprise. The estimated earnings for the next quarter are N/A USD per share.
Does Benitec Biopharma pay dividends?▼
Yes, BNTC.BOATS dividends are paid annual. The last dividend per share was 0 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Benitec Biopharma complete a stock split?▼
Benitec Biopharma has not had any recent stock splits.